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Vaccinia virus immunization provides protec-
tion against variola virus, the causative agent of 
smallpox, and stands as the classic example of a 
successful vaccine. However, the mechanisms 
by which this profound protection is mediated 
are not completely understood. For instance, 
although vaccinia virus–induced antibody re-
sponses have been shown to be necessary and 
suffi  cient for protection against monkeypox 
virus (1), virus-specifi c T cell responses generated 
at the time of vaccination may still contribute to 
eff ective protection. In addition, monkeypox 
infection in macaques may not completely re-
capitulate variola infection in humans and may 
serve as an inadequate model for protective 
immunity against smallpox.
It is known that CD8+ T cells play an im-
portant role in immunity to multiple viruses. 
This has been shown both in pathogens that 
are controlled by the host immune response, 
such as CMV and EBV (2), and pathogens that 
ultimately defeat it, such as HIV/simian immuno-
defi ciency virus (3–11). Virus-specifi c CD8+ 
T cells contribute to viral control by directly 
killing virus-infected cells, secreting antiviral 
factors, and secreting factors that recruit other 
cells of the immune system (12). Although 
virus-specifi c CD8+ T cells are often measured 
by a limited number of parameters, such as 
IFN-γ and/or IL-2 secretion, the functional 
profi le of T cells is certainly more diverse, and 
the combination of functions that confer pro-
tection from infection are uncertain.
Recent advances in the number of para-
meters that can be simultaneously detected by 
fl ow cytometry allow more extensive character-
ization of T cell eff ector functions at the single-
cell level (13). Using this technology, we recently 
examined fi ve functions of CD8+ T cells (surface 
CD107a mobilization for degranulation and 
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IFN-γ, IL-2, macrophage infl ammatory protein [MIP] 1β, 
and TNF-α production) in HIV-infected progressors and 
nonprogressors and found that nonprogressors preferentially 
maintain HIV-specifi c CD8+ T cells that eff ect all fi ve func-
tions on a cell-by-cell basis (14). The association between 
maintenance of this “5+” population of eff ector CD8+ 
T cells and nonprogression suggests that polyfunctional CD8+ 
T cells are an important component of a protective immune 
response. However, whether a vaccine can induce sustained 
levels of polyfunctional T cells and whether such responses 
are associated with protection against viral challenge are 
unknown. In this context, we studied vaccinia virus–specifi c 
T cell immune responses in a randomized, placebo-controlled 
study of modifi ed vaccinia virus Ankara (MVA) versus Dryvax 
vaccination (15). The protocol was designed to test whether 
preimmunization with MVA results in protection from sub-
sequent challenge with the vaccine strain Dryvax, a surrogate 
for variola infection (15).
We used polychromatic fl ow cytometry to characterize 
the functional and phenotypic profi le of MVA and Dryvax-
induced, antigen-specifi c CD8+ T cells in subjects enrolled 
in this clinical trial. As a subsequent step, we also examined 
the functional profi le of HIV-specifi c CD8+ T cells induced 
by immunization with a recombinant NYVAC vaccine engi-
neered to express HIV-1 clade C Env, Gag, Pol, and Nef. 
We show that immunization with replication-competent or 
attenuated vaccinia virus induces CD8+ T cells that are highly 
polyfunctional but express an unusual memory phenotype. 
This polyfunctionality is associated with high levels of IFN-γ 
production, which likely indicates that these CD8+ T cells 
are potent eff ectors.
RESULTS
MVA and Dryvax induce a similar CD8+ T cell 
functional profi le
Vaccinia virus–naive individuals were challenged with Dryvax 
after preimmunization with one or more doses of MVA or 
placebo (Table I). To measure CD8+ T cell responses in-
duced by MVA immunization and Dryvax challenge, we used 
polychromatic fl ow cytometry to measure fi ve T cell functions 
independently and simultaneously: surface CD107a mobili-
zation (degranulation) and IFN-γ, IL-2, MIP-1β, and TNF-α 
induction after in vitro stimulation. Vaccinia virus–specifi c 
CD8+ T cell frequencies were similar whether vaccinia virus 
or MVA was used for in vitro stimulation (Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20062363/DC1). 
Therefore, we used vaccinia virus infection of PBMCs to 
measure CD8+ T cell responses in all donors. Our antibody 
panel and gating strategy enable identifi cation of CD8+ T cells 
exhibiting each and every combination of these fi ve func-
tions (Fig. 1 A). IFN-γ, MIP-1β, and TNF-α production 
dominated the response to vaccinia virus (Fig. 1 B), as nearly 
all of the responding CD8+ T cells produced these cytokines. 
In contrast, only about half of the responding CD8+ T cells 
mobilized CD107a and even fewer produced IL-2 after vac-
cinia virus stimulation. This response pattern was observed 
after MVA immunization and after Dryvax challenge in both 
the MVA and placebo groups.
Total frequencies of vaccinia virus–specifi c CD8+ T cells 
were calculated by summing the frequencies of CD8+ T cells 
within each unique combination of functions (Fig. 1 C). 
Thus, each responding cell was counted only once. Before 
Dryvax challenge (green bars), MVA-induced CD8+ T cell 
responses were detected only in individuals who received 
multiple MVA immunizations. Importantly, responses were 
not detected in the placebo (0× MVA) group before Dryvax 
challenge. This serves as a control for nonspecifi c stimulation 
by vaccinia virus infection in vitro. Although there was no 
diff erence between the frequencies of total vaccinia virus–
specifi c CD8+ T cells before Dryvax challenge in individuals 
who received placebo or one dose of MVA (P = 0.085), two 
doses of MVA induced higher frequencies of vaccinia virus–
specifi c CD8+ T cells than one dose (P = 0.013). After 
Dryvax challenge (red and blue bars), CD8+ T cell responses 
were detected in all individuals; however, frequencies were 
highest in individuals who were preimmunized with two or 
three doses of MVA, and their responses persisted through 
3 mo after challenge. Specifi cally, three preimmunizations with 
MVA resulted in much higher frequency responses after 
Dryvax challenge than the placebo (P = 0.011) or one MVA 
preimmunization (P = 0.013).
Simultaneous measurement of fi ve functions allows 
 detailed assessment of response quality. The vaccinia virus–
specifi c CD8+ T cell response revealed a polyfunctional response 
pattern predominantly consisting of cells exhibiting three or 
more functions (Fig. 1 D). This functional profi le was in-
duced by both MVA and Dryvax regardless of preimmuniza-
tion with MVA. Notably, 25% of the total response 
consisted of cells positive for all fi ve functions. The major 
populations of polyfunctional cells included those positive for 
IFN-γ, MIP-1β, and TNF-α. CD107a expression and/or 
IL-2 production were also detected in combination with 
these cytokines, but populations with these functions con-
tributed less to the overall response.
Polyfunctional CD8+ T cells produce more IFN-𝛄 per cell 
than cells that make only IFN-𝛄
Within a given sample, the median fl uorescence intensity 
(MFI) of each functional parameter is related to the 
quantitative expression of that function on a per-cell basis. 
Thus, the relative amount of each cytokine and chemokine 
Table I. VRC 201 study protocol
Group n MVA/sham 
immunization 
schedule (mo)
Dryvax 
challenge 
(mo)
1 6 0 3
2 8 0, 1 4
3 5 0, 1, 3 6
Placebo 8 Various Variousa
aDryvax given 3 mo after last sham immunization.
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per cell can be measured for each functional population. Pre-
vious studies have shown that vaccine-induced, polyfunc-
tional CD4+ T cell responses in mice produce more IFN-γ 
on a per-cell basis than mono- or bifunctional cells (16). 
Importantly, these studies showed that MFI measured by in-
tracellular cytokine staining directly correlated with secretion 
of the cyto kines measured by ELISA. Using MFI analysis, 
we also found an association between IFN-γ MFI and the 
degree of polyfunctionality (Fig. 2). Specifi cally, cells with 
increasing numbers of functions had higher IFN-γ MFIs 
and, thus, produced more cytokine per cell. Surface mobili-
zation of CD107a appeared to be irrelevant for this associa-
tion; cells producing all cytokines had the highest IFN-γ 
MFI regardless of CD107a expression (unpublished data). 
Figure 1. Vaccinia virus–specifi c CD8+ T cells are highly polyfunc-
tional. (A) Representative example of the gating strategy used to defi ne 
31 functional response combinations of CD8+ T cells. Single function 
gates were set based on negative control (unstimulated) samples and were 
placed consistently across samples. (B) The percentage of the total CD8+ 
T cell response is shown. The frequency of CD8+ T cells expressing each 
function was divided by the frequency of the total response. All MVA dose 
groups were combined into one group for analysis. (C) Magnitude of CD8+ 
T cell responses before and after Dryvax challenge in each preimmunization 
group. (D) Functional composition of the CD8+ T cell response. Every 
possible combination of responses is shown on the x axis. Responses are 
grouped and color coded according to the number of functions. The data 
are summarized by the pie charts, in which each slice of the pie represents 
the fraction of the total response that consists of CD8+ T cells positive for 
a given number of functions. All MVA dose groups were combined into 
one group for analysis (as in B). Boxes represent interquartile ranges; 
mean and SD lines are shown. Bars indicate the percentage of the total 
response contributed by CD8+ T cells with a given functional response.
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These data demonstrate that a single polyfunctional CD8+ T 
cell makes 5–10 times more IFN-γ than a single monofunc-
tional CD8+ T cell. MFI analysis of other cytokines did not 
reveal such an association.
Vaccinia virus–specifi c CD8+ T cells have an 
unusual phenotype
We costained with cell surface markers to determine the sur-
face phenotype of vaccinia virus–specifi c CD8+ T cells (Fig. 3). 
Costaining revealed an unusual surface phenotype for mem-
ory cells: CD27 (dull), CD45RO (−), CD57 (−), CD11a (dull), 
and CC chemokine receptor (CCR) 7 (−). Further staining 
revealed that CD45RO− cells were CD45RA+ (unpublished 
data). Although vaccinia virus–specifi c CD8+ T cells coex-
pressed CD45RA and CD27, they were clearly not naive; 
CD27 staining was dimmer than that of naive cells. This phe-
notype was maintained through several months after Dryvax 
challenge (Fig. 3 A) and was exhibited by vaccinia virus–
specifi c CD8+ T cells regardless of their functional profi le 
(Fig. 3 B). Additionally, despite the unusual phenotype, these 
cells appear to be long lived; we have detected polyfunctional, 
vaccinia virus–specifi c CD8+ T cells exhibiting this unusual 
phenotype in an individual 5 yr after Dryvax immunization 
(unpublished data).
Induction of polyfunctionality and unique phenotype is not 
a consequence of vaccinia virus stimulation in vitro
In previous experiments, we examined the function and phe-
notype of CD8+ T cells specifi c for HIV, CMV, EBV, and 
infl uenza and found them to be less polyfunctional than 
the responses to vaccinia virus we report in this paper (14). 
In addition, the phenotype of these virus-specifi c CD8+ 
T cells was distributed mainly between CD45RO+CD27+ 
and CD45RO+CD27– populations. We opined that the 
phenotype and function of vaccinia virus–specifi c CD8+ T cells 
observed in this study could be caused by use of a live virus stim-
ulation (compared with the peptides used in previous studies). 
We therefore performed several experiments to address this 
possibility. HLA-A2 tetramers loaded with three diff erent vaccinia 
virus peptides were used to identify vaccinia virus–specifi c 
CD8+ T cells. Unstimulated, tetramer-positive CD8+ T cells 
displayed the same phenotype as multifunctional cells detected 
after vaccinia virus stimulation (Fig. 4 A). In addition, peptide 
was used to stimulate CD8+ T cells from HLA-A2+ donors after 
Dryvax challenge. In both phenotype and function, peptide-
specifi c CD8+ T cell responses were similar to those detected 
after live vaccinia virus infection (Fig. 4 B).
An additional experiment was performed to confi rm that 
the functional profi le and phenotype of virus-specifi c CD8+ 
T cells detected by virus infection in vitro was similar to that 
detected after peptide stimulation. Vaccinia virus recombi-
nants expressing HIV-1 clade B Gag were used to stimulate 
HIV Gag-specifi c CD8+ T cell responses from HIV-1–
 infected individuals. Gag-specifi c CD8+ T cells had the same 
phenotype and function whether stimulated with the vac-
cinia virus recombinant or overlapping Gag peptides, and dif-
fered markedly from the phenotype and function of vaccinia 
virus–specifi c CD8+ T cells (Fig. 4 C).
Collectively, these results show that vaccinia virus–
specifi c CD8+ T cells express a polyfunctional, CD45RO–
CD27intermediate phenotype that refl ects the nature of the specifi c 
response generated to the vaccination in vivo. A similar surface 
marker phenotype was also recently reported in a melanoma 
tumor antigen-recombinant MVA vaccine trial (17).
Persistence of vaccinia virus–specifi c CD8+ T cell clonotypes 
through 3 mo after Dryvax
Given the unique surface phenotype of vaccinia virus–specifi c 
CD8+ T cells, we wanted to confi rm that these cells persist 
through 3 mo after Dryvax and exclude the possibility that 
cells were being recruited from a preexisting pool of memory 
T cells. Therefore, we performed TCR clonotyping on sorted, 
tetramer-positive CD8+ T cells at 1 and 3 mo after Dryvax. 
The same clonotypes were identifi ed at both 1 and 3 mo after 
Dryvax (Fig. 5). Importantly, clonotypes with identical CDR3 
amino acid sequences were also identical at the nucleotide 
level (unpublished data). Additionally, the hierarchy of clono-
types was similar at both time points. This strongly suggests 
that vaccinia virus–specifi c memory CD8+ T cells that persist 
through 3 mo after immunization are derived from the same 
pool of cells that existed at 1 mo after immunization.
Figure 2. Polyfunctional cells make more IFN-𝛄 per cell than 
monofunctional cells. (A) IFN-γ fl uorescence of CD8+ T cells with dif-
ferent functional properties. Representative example from one individual. 
(B) Compiled IFN-γ MFI of CD8+ T cells of all cytokine combinations (n = 24). 
Boxes represent interquartile ranges; means and SDs are indicated (note 
that the average MFI for the IFN-γ− populations is 446).
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Vaccinia virus–specifi c CD8+ T cells contain granzymes 
and perforin
About half of vaccinia virus–specifi c CD8+ T cells exhibited 
surface mobilization of CD107a in response to virus stimula-
tion. Therefore, we combined tetramer and intracellular staining 
to examine the granzyme and perforin content of vaccinia 
virus–specifi c CD8+ T cells. Nearly all tetramer-positive cells 
contained granzyme A, most contained granzyme B, and 
up to half were perforin positive (Fig. 6). This suggests that 
vaccinia virus–specifi c CD8+ T cells have the ability to kill 
virus-infected cells.
HIV-1–specifi c CD8+ T cells induced by an HIV recombinant 
vaccinia virus are highly polyfunctional
We posited that HIV-specifi c CD8+ T cells induced by an HIV 
recombinant vaccinia virus vaccine should express the func-
tion and phenotype of vaccinia virus–specifi c CD8+T cells. 
We therefore measured T cell responses in fi ve individuals 
immunized as part of the EuroVacc vaccine protocol with 
DNA prime/NYVAC HIV-1 clade C recombinant boost 
(unpublished data). An HLA-A1–restricted CD8+T cell re-
sponse to the Env peptide YSENSSEYY was detected in all 
fi ve donors (unpublished data). We found that the functional 
profi le and phenotype of Env-specifi c CD8+ T cells induced 
by vaccination was similar to the vaccinia virus vector-specifi c 
CD8+ T cell response (Fig. 7). Env-specifi c CD8+ T cells were 
highly polyfunctional and exhibited a similar phenotype as 
vaccinia virus–specifi c CD8+ T cells. These data show that the 
function and phenotype of vaccinia virus vector-specifi c CD8+ 
T cell responses extend to inserts expressed within the vector.
D I S C U S S I O N 
Immunization with vaccinia virus induces lifelong protection 
from smallpox and can serve as a benchmark for the type of 
immunity that other vaccines should induce. Vaccinia virus–
specifi c CD8+ T cells are induced after immunization (18–20), 
and some HLA-restricted peptides have been identifi ed (21, 22). 
Vaccination strategies using recombinant vaccinia viruses are 
currently being tested in clinical trials. In this paper, we report 
that (a) attenuated vaccinia virus strains such as MVA and 
NYVAC induce polyfuctional CD8+ T cell responses similar 
to those of the completely replication-competent Dryvax strain, 
(b) polyfunctional CD8+ T cells make much more IFN-γ 
than cells with fewer functions, (c) vaccinia virus–induced 
CD8+ T cells express an unusual phenotype (CD45RO−
CD27intermediate), and (d) DNA prime/HIV recombinant 
 NYVAC boost vaccinations induce polyfunctional CD8+ 
T cells specifi c for the inserted HIV genes.
Figure 3. Vaccinia virus–specifi c CD8+ T cells have an unusual 
phenotype. (A) Several surface markers were included in the multicolor 
fl ow cytometry panel to defi ne the phenotypes of vaccinia virus–specifi c 
CD8+ T cells. To incorporate these markers into the panel, responding cells 
were identifi ed by staining with Alexa Fluor 680–CD107a and IFN-γ, TNF-α, 
or IL-2 (each conjugated to APC). A CD27-PE antibody conjugate was 
used to allow for the best discrimination of expression. The phenotype of 
CD107a+cytokine+ CD8+ T cells is shown as a red contour plot overlayed 
on a density plot of the total CD8+ T cell population at 1 and 5 mo after 
Dryvax challenge in a representative individual from the MVA immuniza-
tion group. (B) The vaccinia virus–specifi c CD8+ T cell phenotype is similar 
among cells of different functional properties. 5+ (CD107a+IFN-γ+IL-2+
MIP-1β+TNF-α+), 4+ (CD107a+IFN-γ+IL-2–MIP-1β+TNF-α+), and 3+ 
(CD107a–IFN-γ+IL-2–MIP-1β+TNF-α+) CD8+ T cells are overlayed as con-
tour plots on density plots of the total CD8+ T cell population.
1410 VACCINIA VIRUS-INDUCED CD8+ T CELL RESPONSES | Precopio et al.
Figure 4. The unusual phenotype of vaccinia virus–specifi c CD8+ 
T cells is not a consequence of in vitro stimulation. (A) Representative 
KVD, CLT, and ILD tetramer staining of HLA-A2+ vaccinees after Dryvax 
challenge plotted as tetramer versus side scatter–area (SSC-A). Numbers 
indicate the percentage of CD8+ T cells that are tetramer positive. CD27 
and CD45RO expression on tetramer-binding cells is shown as red con-
tour plots overlayed on density plots of the total CD8+ T cell population. 
(B) PBMCs from HLA-A2+ vaccinees were stimulated with peptide for 6 h 
or vaccinia virus for 9 h. Data from a representative stimulation with KVD 
is displayed (as in Fig. 1 D). The phenotype of vaccinia virus–specifi c CD8+ 
T cells is shown as a red contour plot overlayed on a density plot of the 
total CD8+ T cell population. To best separate the CD27 high, intermedi-
ate, and low populations, a PE-conjugated antibody was used for staining. 
To accommodate this change from the standard antibody panel, the anti–
MIP-1β antibody was omitted. Therefore, the contour plot shows the 
phenotype of CD107a+IFN-γ+IL-2+TNF-α+ CD8+ T cells, which (as shown 
by the bar graph) also produce MIP-1β. (C) PBMCs from HIV-1–infected 
individuals were stimulated for 6 h with overlapping Gag peptides 
or for 9 h with Gag recombinant vaccinia virus. Data from a representative 
individual is shown. The contour plots show the phenotype of 
CD107a+IFN-γ+IL-2–TNF-α+ CD8+ T cells.
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A safer alternative to Dryvax is sought because of the high 
rate of serious complications in the general population, the 
increased risk in specifi c populations (including the immuno-
compromised and those affl  icted with eczematous skin disease), 
and the potential need for global orthopoxvirus immunity for 
protection against a bioterrorist threat. MVA is an attenuated 
strain that exhibits very limited replication in mammalian 
cells and does not disseminate in the host (23, 24). It may 
therefore represent a safer alternative than Dryvax. NYVAC 
was derived from the VACV strain Copenhagen, from which 
18 genes, encoding proteins involved in host range and viru-
lence, were deleted (25). Two doses of MVA have been 
shown to protect macaques from lethal monkeypox challenge 
(26); however, its immunogenicity and ability to provide 
protection against smallpox in humans has not been tested. 
In this paper, we report that both MVA and Dryvax induce 
highly polyfunctional CD8+ T cells that can respond by 
degranulating and producing IFN-γ, TNF-α, and MIP-1β, 
with or without IL-2. This suggests that extensive replication 
of the virus in vivo is not required to induce polyfunctional 
CD8+ T cell responses in that the same functions were 
induced by replication-competent Dryvax and replication-
defective MVA. However, it is important to note that, whereas 
one immunization with Dryvax induced measurable responses 
in vaccinia virus–naive individuals, more than one dose of MVA 
was required for detection of vaccinia virus–specifi c CD8+ 
T cells before Dryvax challenge.
The induction and maintenance of highly polyfunctional, 
virus-specifi c CD8+ T cells after immunization with vaccinia 
virus is consistent with our observation that polyfunctional 
CD8+ T cell responses are present in subjects with well-
controlled virus infections such as EBV, CMV, infl uenza, 
and nonprogressive HIV-1 (14, 27, 28). This suggests that 
maintenance of highly polyfunctional, virus-specifi c CD8+ 
T cells is benefi cial and contributes to eff ective antiviral im-
munity. Although polyfunctional CD8+ T cells characterize 
the response to vaccinia virus and nonprogressive HIV infec-
tion, the specifi c functional combinations diff er between the 
two responses. For example, vaccinia virus induces a popula-
tion of CD8+ T cells eff ecting four functions (IFN-γ, IL-2, 
MIP-1β, and TNF-α) that is very low in HIV nonprogres-
sors and not detected in HIV progressors (14). Additionally, 
the dominant three-functional CD8+ T cell populations 
induced also diff er between vaccinia virus (IFN-γ, MIP-1β, 
and TNF-α) and nonprogressive HIV infection (CD107a, 
IFN-γ, and MIP-1β). TNF-α production diff ers between 
Figure 5. Clonal analysis of sorted CD8+ T cells specifi c for KVD 
at 1 and 3 mo after Dryvax. CDR3 amino acid sequence and percent 
frequency and TCRBJ usage are shown for each clonotype defi ned by its 
CDR3. Sequences with identical amino acid residues are shown in 
color. Tetramer frequencies are shown as a percentage of total CD8+ 
T cells. Data are from one individual.
Figure 6. Vaccinia virus–specifi c CD8+ T cells express intracellular 
granzymes and perforin. Perforin and granzyme expression on KVD 
tetramer-binding cells is shown as red contour plots overlayed on density 
plots of the total CD8+ T cell population. An APC-conjugated tetramer 
was used in A; a PE-conjugated tetramer was used in B. Representative 
staining from one of three donors.
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the vaccinia virus– and HIV-specifi c response; more than half 
of vaccinia virus–specifi c CD8+ T cells produce this cyto-
kine, whereas less than half of HIV-specifi c CD8+ T cells 
make TNF-α. Thus, the functional profi les of virus-specifi c 
CD8+ T cells are dependent on the infecting virus and may 
refl ect diff erences in cell tropism or activation through diff er-
ent antigen-processing pathways.
Polyfunctional CD4+ T cells correlate with protection 
from Leishmania major and Mycobacterium tuberculosis in a mouse 
model (16). Detailed analysis of the L. major–specifi c CD4+ 
T cell response revealed that not only was the quality of the 
response more polyfunctional in protected mice but that 
polyfunctional cells produced more cytokine per cell than 
monofunctional CD4+ T cells. Our data are consistent with 
these observations in that vaccinia virus–specifi c, polyfunc-
tional CD8+ T cells produce larger amounts of IFN-γ per 
cell than cells with fewer functions. This suggests that these 
polyfunctional CD8+ T cells are potent eff ectors and may 
explain, in part, why they are associated with viral control.
Virus-specifi c CD8+ T cells induced by MVA, NYVAC, 
and Dryvax express CD45RA and CD27. CD45RA is the 
high molecular mass isoform of CD45, a phosphatase involved 
in regulating T cell signal transduction by activation of Src 
family protein tyrosine kinases such as Lck and inhibition of 
Janus kinases (for review see reference 29). CD27 is a mem-
ber of the TNF receptor family and functions as a co-stimulatory 
molecule (30). Although coexpression of CD45RA and 
CD27 is often used to defi ne naive T cells (31), the intensity 
of CD27 staining on vaccinia virus–specifi c CD8+ T cells is 
intermediate between CD27-high and -low populations and 
does not coincide with the naive T cell population. Interme-
diate CD27 expression has been previously reported on 
CMV-specifi c CD8+ T cells and was associated with rapid 
cytokine production; expression of granzyme B, perforin, 
and CD57; and lack of CD28 expression (31, 32). Vaccinia 
virus–specifi c CD8+ T cells diff er in that they lack CD57 
but are otherwise similar in their expression of eff ector 
molecules. Thus, they are likely good eff ectors that are main-
tained as long-term memory cells. Although it is now 
well-established that some memory CD8+ T cells express 
CD45RA, it is unusual that vaccinia virus–specifi c CD8+ 
T cells express this isoform as early as 1 mo after vaccination 
and through 3 mo after vaccination. Phenotypic analyses 
of primary and persistent EBV- and CMV-specifi c CD8+ 
T cells have shown predominant CD45RO expression during 
acute infection with the acquisition of CD45RA expression 
on some virus-specifi c CD8+ T cells months thereafter (33–35). 
A small proportion of vaccinia virus–specifi c CD8+ T cells 
do express CD45RO at 1 and 3 mo after vaccination, which 
may indicate that CD45RO expression was more prevalent 
within the fi rst month after vaccination, before sampling. 
CD45RA versus RO expression can also be associated with 
epitope-specifi city (34, 35); however, we found a similar dis-
tribution of CD45RA+ and CD45RO+ cells specifi c for 
three diff erent vaccinia virus–derived peptides as for whole 
virus (Fig. 4).
Expression of CCR7 marks long-lived, central memory 
cells that home to lymph nodes and can diff erentiate into 
eff ectors upon reexposure to antigen (36). Although vaccinia 
virus–specifi c CD8+ T cells did not express CCR7 through 
5 mo after vaccination, long-term T cell immunity after Dryvax 
immunization has been documented (37–39). Therefore, it is 
possible that CCR7 expression is gained at later time points 
after vaccination, that CCR7+ vaccinia virus–specifi c CD8+ 
T cells reside in lymph nodes and do not recirculate through 
the peripheral blood early after vaccination, or that expression 
of CCR7 is not a requisite marker for maintenance of long-
lived vaccinia virus–specifi c CD8+ T cells.
Figure 7. Env-specifi c CD8+ T cells induced by an HIV recombinant 
vaccinia virus are highly polyfunctional. Functional composition of the 
CD8+ T cell response specifi c for the vaccinia virus vector and Env insert 
displayed (as in Fig. 1 D). The phenotype of 5+ (CD107a+IFN-γ+IL-
2+TNF-α+MIP-1β+) CD8+ T cells from one representative individual is 
shown as red contour plots overlayed on density plots of the total CD8+ 
T cell population. Mean bars and SD lines are shown.
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The ability of MVA to induce polyfunctional CD8+ T 
cell responses suggests that safer, attenuated vaccinia virus strains, 
such as MVA and NYVAC, may be useful vaccine platforms 
for other viruses, such as HIV. However, several reports in 
mice and humans (17, 40), as well as our preliminary studies, 
have found that recognition of recombinant gene inserts is 
poor. Vaccination strategies using a DNA prime followed by 
recombinant vaccinia virus boost increase immunogenicity of 
the recombinant antigen expressed by the viral vector (41). 
After two DNA primes and two recombinant NYVAC boosts, 
highly polyfunctional CD8+ T cells specifi c for inserted HIV 
gene products are induced.
In summary, virus-specifi c CD8+ T cells induced by vac-
cinia virus immunization are highly polyfunctional and pheno-
typically unusual. This polyfunctional CD8+ T cell profi le 
is induced to both the vector and inserts and is consistent 
with virus- specifi c CD8+ T cell responses observed in well-
controlled, persistent infections such as CMV, EBV, and non-
progressive HIV-1 infection. Vaccine-induced polyfunctional, 
but not IFN-γ monofunctional, T cells have been shown to 
correlate with protection of mice against L. major challenge. 
Collectively, these data indicate that vaccines able to elicit poly-
functional T cells are desirable, and suggest that the reason that 
Dryvax off ers exquisite protection against smallpox infection is its 
inherent ability to induce highly polyfunctional T cell responses.
MATERIALS AND METHODS
Vaccine research center (VRC) 201 study protocol. VRC 201 was a 
randomized, double-blind, placebo-controlled study that enrolled 76 
healthy, vaccinia virus–naive adults from 18 to 33 yr of age to receive (a) one 
dose of vaccinia virus (Dryvax); (b) 1, 2, or 3 intramuscular doses of MVA 
(Therion Biologics Corporation); or (c) placebo followed by a Dryvax chal-
lenge 12 wk after the last dose of MVA/placebo. The primary objective of 
the study was to evaluate the safety of MVA and to identify a schedule of 
MVA that provides evidence of clinical protection from vaccinia virus chal-
lenge. The secondary objective was to examine the immunogenicity of MVA 
and Dryvax, as determined by vaccinia virus–specifi c neutralizing antibody, 
binding antibody, and T cell responses measured by fl ow cytometric detection 
of intracellular cytokines. A complete analysis of the primary objective, 
as well as local and systemic reactogenicity of vaccination, is presented 
elsewhere (15).
A subset (27 subjects) of the study participants was chosen for more 
extensive evaluation of their vaccinia virus–specifi c T cell responses based on 
the number of cells available and the magnitude of their response. Results 
obtained using this subset of donors do not appear to be skewed by these 
selection criteria; within this group, donors with high frequency CD8+ T 
cell responses had similar functional profi les as those with low frequency 
responses. All study participants gave informed consent, and the study was 
approved by the NIAID Institutional Review Board (NIH 02-I-0316).
EuroVacc study protocol. HIV-negative volunteers received two DNA 
primes (weeks 0 and 4), followed by two recombinant NYVAC boosts (weeks 
20 and 24). The NYVAC was engineered to express HIV-1 clade C Env, Gag, 
Pol, and Nef. A complete analysis of the EuroVacc study is presented else-
where (unpublished data). For our experiments, T cell responses were ana-
lyzed from fi ve vaccinees from a sample obtained 2 wk after the fi nal NYVAC 
boost. This study was approved by the institutional review boards of St Mary’s 
Hospital and Centre Hospitalier Universitaire Vaudois.
Polychromatic fl ow cytometric antibody panels. The following anti-
body panel was used to independently quantify fi ve separate T cell functions: 
CD3-Cy7 allophycocyanin (APC), IFN-γ–FITC, MIP-1β–PE, IL-2–APC, 
TNF-α–Cy7PE (all obtained from BD Biosciences); CD4-Cy5.5PE (Caltag); 
CD45RO-ECD (Beckman Coulter); CD107a–Alexa Fluor 680, CD14-
Cy5PE, CD19-Cy5PE, CD27–Cascade Blue (conjugated according to stan-
dard protocols available at http://drmr.com/abcon/index.html); and 
CD8-QD655 and CD57-QD545 (conjugated as previously described; refer-
ence 42). Unconjugated antibodies were obtained from BD Biosciences; 
Q-Dots, Alexa Fluor 680, and Cascade Blue were obtained from Invitrogen; 
Cy5 was obtained from GE Healthcare; and PE was obtained from Pro-
Zyme. As new reagents became available, and to address additional questions 
regarding T cell responses, the following reagents were also used in various 
combinations: CD27-PE, CD11a-FITC, CCR7-Cy7PE (all obtained from 
BD Biosciences); CD8-QD705, CD27-Cy5PE, CD14–Cascade Blue, and 
CD19–Cascade Blue (conjugated as described); and a violet fl uorescent reac-
tive dye (ViViD; Invitrogen) as a viability marker to exclude dead cells from 
the analysis (43).
Peptides. The vaccinia virus–derived peptides KVDDTFYYV (KVD; pro-
tein 018L74–82) (21), CLTEYILWV (CLT; protein 189R79–87) (21), and 
ILDDNLYKV (ILD; protein 074R18–26) (17) were synthesized by New 
England Peptide, Inc. The HIV-1 peptide YSENSSEYY (clade C Env173–177) 
was synthesized by the Centre Hospitalier Universitaire Vaudois peptide facility. 
Peptides (15-mers overlapping by 11) spanning the HIV-1 clade B Gag pro-
tein were synthesized as previously described (44). Peptides were reconsti-
tuted in DMSO. Gag peptides were pooled, and all peptides were used to 
stimulate cells at a fi nal concentration of 2 μg of each peptide per milliliter.
In vitro stimulation and staining of cells. PBMCs were thawed, resus-
pended at 2 × 106 cells/ml in R10 media (RPMI 1640 supplemented with 
10% heat inactivated fetal calf serum, 100 U/ml penicillin G, 100 μg/ml 
streptomycin sulfate, and 1.7 mM sodium glutamate) containing 10 U/ml 
DNase I (Roche Diagnostics) and rested overnight at 37°C. Restimulation 
with vaccinia virus in vitro was performed using a modifi ed version of the 
method fi rst described by Speller et al. (45). In brief, cells were infected with 
vaccinia virus (multiplicity of infection = 1; Therion Biologics Corporation) 
in 200 μl R10 for 1 h at 37°C. R10 was added to adjust the total volume to 
1 ml, and the cells were incubated for an additional 3 h. At that time, 10 μg/
ml brefeldin A (Sigma-Aldrich), 0.7 μl/ml Golgistop (BD Biosciences), and 
anti-CD107a–Alexa Fluor 680 were added as previously described (46), and 
the cells were mixed and further incubated at 37°C for 5 h. For some experi-
ments, recombinant vaccinia virus expressing HIV-1 Gag (provided by K. 
Luzuriaga, University of Massachusetts Medical Center, Worcester, MA) was 
used for stimulation. Negative control tubes without addition of vaccinia 
virus were included for all samples. Stimulation of cells from the placebo group 
before Dryvax challenge served as an additional negative control.
In some experiments, cells were stimulated with 2 μg/ml peptide for 
5–6 h in the presence of brefeldin A, Golgistop, anti-CD107a–Alexa Fluor 
680, and 1 μg/ml each of anti-CD28 and anti-CD49d. Negative control 
tubes without peptide were also included.
After stimulation, cells were washed in PBS containing 1% bovine 
serum albumin and 0.1% sodium azide and stained with pretitered surface 
antibodies. Cells were washed and permeablized according to the manufac-
turer’s instructions (Cytofi x/Cytoperm Kit; BD Biosciences). After washing 
twice in the supplied buff er, cells were intracellularly stained with pretitered 
antibodies against CD3, cytokines, and chemokines. Cells were subsequently 
washed in the supplied buff er and fi xed in PBS containing 1% paraformalde-
hyde. Fixed cells were stored at 4°C in the dark until fl ow cytometric analysis 
(performed within 24 h).
Flow cytometric analysis. Cells were collected on an LSR II instrument 
(BD Biosciences) confi gured to detect 18 fl uorochromes. 350,000–1,000,000 
events were collected per sample. Analysis was performed using FlowJo soft-
ware (version 6.3; TreeStar, Inc.). Cell doublets were excluded using forward 
scatter (FSC)–area versus FSC-height parameters. To minimize background 
levels of staining caused by nonspecifi c binding of antibodies, Cascade Blue 
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aggregates, CD14+ cells, CD19+ cells, and dead cells were excluded using a 
dump channel. A small lymphocyte gate was created using FSC and side scat-
ter properties. Non–T cells were excluded by gating on CD3+ cells. CD8+ 
T cells were selected by fi rst gating out CD4+ cells and subsequently gating 
on CD8+ cells. Alternatively, CD4+ T cells were selected by fi rst gating out 
CD8+ cells and subsequently gating on CD4+ cells. All T cell markers were 
plotted versus IFN-γ to observe and include stimulated cells that had down-
regulated surface marker expression.
According to this strict selection of CD8+ T cells, functional analysis 
was performed by plotting the expression of each functional marker against 
another, as shown in Fig. 1 A. Boolean combinations of single functional 
gates were created using FlowJo software to determine the frequency of each 
response based on all possible combinations of cytokine, chemokine, and 
CD107a expression. Background responses detected in negative control 
tubes were subtracted from those detected in stimulated samples for every 
specifi c functional combination. The MFI of each functional parameter was 
also determined for all Boolean gate combinations using FlowJo software. 
Frequency and MFI data were output from the table editor of FlowJo for 
formatting in Pestle software (version 1.3; provided by M. Roederer, NIH, 
Bethesda, MD).
Data analysis and statistics. The data analysis program Simplifi ed Presen-
tation of Incredibly Complex Evaluations (version 2.9; provided by M. 
Roederer, NIH, Bethesda, MD) was used to analyze and generate graphical 
representations of T cell responses detected by polychromatic fl ow cytome-
try. All values used for analyzing proportionate representation of responses 
are background subtracted. Hence, these values can be less than zero in cases 
where the background sample had more events in a particular functional gate 
than the positive. Because negative values cannot be easily considered for 
representational analysis (i.e., to graphically represent pie charts), these values 
are set to zero. To avoid a systematic bias introduced by zeroing only nega-
tive values, we set a threshold of 0.013% for this dataset, below which all 
values were set to zero. This value was chosen based on the distribution of 
negative values in the background-subtracted dataset.
Total frequencies of vaccinia virus–specifi c CD8+ T cells were com-
pared between vaccination groups using a two-tailed Student’s t test assum-
ing unequal variances using JMP software (version 5.1; SAS Institute).
HLA-A2 tetramers. Tetrameric recombinant pMHCI antigens were pro-
duced as previously described (47). Biotinylated HLA-A*0201 heavy chains 
refolded with β2 microglobulin and vaccinia virus peptides (BioSynthesis) 
were conjugated by addition of APC-conjugated streptavidin or PE-conjugated 
streptavidin (both obtained from Prozyme) at a 4:1 molar ratio, respectively, 
to produce tetrameric pMHCI complexes. Once prepared, tetramers were 
stored in the dark at 4°C for no longer than 3 mo.
PBMCs were stained with tetramers at 37°C for 15 min. Cells were 
washed in PBS containing 1% bovine serum albumin and 0.1% sodium azide 
and stained with a cocktail of antibodies against the following surface mole-
cules: CD3-Cy7APC, CD8-QD655, CD27-PE, CD45RO-ECD, CD57-
FITC (BD Biosciences), CD14–Cascade Blue, and CD19–Cascade Blue. 
ViViD was also included to exclude dead cells from the analysis.
For granzyme and perforin expression analysis, tetramer staining was 
performed as described followed by surface staining with antibodies against 
CD3-Cy7APC, CD8-QD705, CD27-Cy5PE, CD45RO-ECD, CD57-
QD565, CD14–Cascade Blue, CD19–Cascade Blue, and ViViD. Cells were 
permeablized using the Foxp3 Staining Buff er Set (eBioscience), according 
to manufacturer’s instructions, and intracellularly stained with antibodies 
against granzyme A–PE or –FITC (BD Biosciences), perforin-FITC (BD 
Biosciences), and granzyme B–APC (Caltag).
Flow cytometric sorting. Sorting was performed on stained cells using a 
modifi ed FACS DIVA (Becton Dickinson). Instrument setup was performed 
according to the manufacturer’s instructions. All sorts were performed at 
25 PSI. Electronic compensation was conducted with antibody-capture beads 
(BD Biosciences) stained separately with individual mAbs used in the stained 
samples. Small, live CD3+CD14−CD19−CD4−CD8+ KVD tetramer–positive 
cells were sorted directly into 1.5-ml microtubes containing 100 μl RNAlater 
(Ambion) for clonotype analysis. 4,500 and 5,000 cells were collected for 1 
and 3 mo after Dryvax challenge, respectively.
TCR clonotype analysis. After cell lysis, mRNA was extracted (Oligotex 
Kit; QIAGEN) and subjected to a nonnested, template switch–anchored 
RT-PCR using a 3′ TCRB constant region primer (5′-G C T T C T G A T G G-
C T C A A A C A C A G C G A C C T C -3′), as described previously (48). Amplifi ed 
products were ligated into pGEM-T Easy Vector (Promega) and cloned by 
transformation of competent DH5α Escherichia coli. Selected colonies were 
amplifi ed by PCR using standard M13 primers and sequenced from an insert-
specifi c primer using fl uorescent dye terminator chemistry (Applied Bio-
systems). 72 and 75 clones were generated and analyzed at 1 and 3 mo after 
Dryvax challenge, respectively. Pseudogenes and “nonfunctional” sequences 
that could not be resolved after inspection of the individual chromatograms 
were discarded from the analysis. Nucleotide comparisons were used to estab-
lish clonal identity. Data analysis was performed using Sequencher software 
(version 4.2; Gene Codes Corporation). The international ImMunoGeneTics 
nomenclature system was used for TCRBV and TCRBJ (49).
Online supplemental material. In Fig. S1, PBMCs were infected over-
night with Dryvax or MVA. Intracellular IFN-γ/IL-2 staining was used to 
measure the frequency of responding CD8+ T cells. Response frequencies 
were similar whether Dryvax or MVA was used for stimulation after MVA 
immunization alone or MVA plus Dryvax. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20062363/DC1.
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